Zika/dengue vaccine and application thereof
AssigneeInstitute of Microbiology, Chinese Academy of Sciences
InventorsFu GAO, Lianpan DAI, Jinghua YAN, Kun XU, Yuxuan HAN, Qihui WANG, Qingrui HUANG, Jinhe LI
Life of this patent
Estimating the term…
Abstract
Provided in the present disclosure are a Zika/dengue vaccine and its application thereof. The present disclosure introduces a mutation into the E-protein FL fusion region of the Zika virus or dengue virus. Antigens with said mutations are unable to bind to antibodies that causes ADE. After immunization with the vaccine of the present disclosure acquired from the said antigens, production of FL epitope-induced antibodies can be prevented, thereby reducing or eliminating the ADE effect.
Claims20
An antigen having an E protein FL fusion region of Zika virus or dengue virus, wherein the E protein FL fusion region comprises one of the following mutations:
- (1) one or two of D98 and N103 site mutations in combination with a three-site mutation of G106, L107 and F108;
- (2) one of G106, L107, and F108 site mutations or their combinations;
- and
- (3) a single-site mutation of W101.
An antigen binding epitope of the E protein FL fusion region of Zika virus, wherein the E protein FL fusion region of Zika viruses comprises the amino acid sequence of D98-R99-G100-W101-G102-N103-G104-C105-G106-L107-F108-G109, which comprises one of the following mutations:
- (1) one or two of D98 and N103 site mutations in combination with a three-site mutation of G106, L107 and F108;
- (2) one of G106, L107, and F108 site mutations or their combinations;
- and
- (3) a single-site mutation of W101.
An antigen binding epitope of the E protein FL fusion region of dengue virus, wherein the E protein FL fusion region of dengue virus comprises the amino acid sequence of D98-R99-G100-W101-G102-N103-G104-C105-G106-L107-F108-G109, which comprises one of the following mutations:
- (1) one or two of D98 and N103 site mutations in combination with a three-site mutation of G106, L107 and F108;
- (2) one of G106, L107, and F108 site mutations or their combinations;
- and
- (3) a single-site mutation of W101.
Dependencies are inferred from the claim text.